Health
Targeted therapies developed to reduce lung fibrosis – Medical Xpress
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.
People with idiopathic pulmonary fibrosis (IPF) have a life expectancy of less than five years. Fibrotic diseases cause organ failure that lead to about 45% of all deaths in the United States. Existing therapies do little to slow progression.
Now, Philip S. Low, the Purdue Ralph C. Corley Distinguished Professor of Chemistry and Presidential Scholar…
-
Noosa News21 hours agoEnsure voices are heard – Proctor
-
Business18 hours agoUp 34% this year, can Challenger shares keep rising according to Macquarie?
-
Noosa News23 hours agoCity of Moreton Bay claims homeless people consented to having camps thrown away
-
General22 hours agoReserve Bank board still looking for yesterday’s news